Low levels of the vascular endothelial growth factor in CSF from early ALS patients.
Deletion of the hypoxia-response element in the vascular endothelial growth factor (VEGF) promoter causes motor neuron degeneration in a mouse model. "At-risk" haplotypes with low circulating VEGF levels have been demonstrated in humans. Here the authors report low VEGF levels in the CSF of ALS patients during their first year of the disease, independently of VEGF promoter polymorphism. This finding early in ALS patients suggests a possible role for VEGF gene regulation in the pathogenesis of ALS.
Devos
D
D
Department of Neurology, R. Salengro Hospital, Lille, France.
Moreau
C
C
Lassalle
P
P
Perez
T
T
De Seze
J
J
Brunaud-Danel
V
V
Destée
A
A
Tonnel
A B
AB
Just
N
N
D000368:Aged; D000690:Amyotrophic Lateral Sclerosis / Q000097:blood / Q000134:cerebrospinal fluid* / Q000209:etiology; D018450:Disease Progression; D005260:Female; D006239:Haplotypes; D006801:Humans; D000860:Hypoxia / Q000209:etiology; D008297:Male; D008875:Middle Aged; D011401:Promoter Regions, Genetic / Q000235:genetics; D013997:Time Factors; D042461:Vascular Endothelial Growth Factor A / Q000097:blood / Q000134:cerebrospinal fluid / Q000172:deficiency* / Q000235:genetics / Q000502:physiology
C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A